Guardant Health to acquire fellow cancer diagnostic company Bellwether Bio

Liquid biopsy company Guardant Health said it will advance its early detection product pipeline by acquiring Bellwether Bio for an undisclosed sum.

Bellwether Bio Inc. (Seattle, Wash.) is developing cancer diagnostics based on the epigenomics of cell-free DNA (cfDNA). Guardant Health Inc. (NASDAQ:GH) said "early research has shown the strong potential impact of incorporating biologically relevant epigenomic information on the clinical performance of blood tests for early stage cancer detection."...